Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA’s Center for Veterinary Medicine and Announces Ashlee E. Watts, DVM, PhD, DACVS as Principal Investigator
OXNARD, Calif.–(BUSINESS WIRE)–Celavet Inc., a regenerative medicine company developing stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals, and a subsidiary of Celavie Biosciences, LLC, today announced Ashlee E. Watts, DVM, PhD, DACVS as principal investigator for a new equine tendinitis study being submitted to the FDA’s Center for Veterinary Medicine (CVM).
